BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zomorodi K, Kankam M, Lu Y. A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food. Clinical Therapeutics 2019;41:196-204. [DOI: 10.1016/j.clinthera.2018.12.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 El-Solh AA, Rudraraju A, Pasrija D, Bui H. Pharmacotherapy of residual excessive sleepiness among continuous positive airway pressure (CPAP) treated patients with sleep apnea. Expert Opin Pharmacother 2022;:1-10. [PMID: 35045769 DOI: 10.1080/14656566.2022.2029408] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zaccara G, Bartolini E, Tramacere L, Lattanzi S. Drugs for patients with epilepsy and excessive daytime sleepiness. Epilepsy Behav 2021;124:108311. [PMID: 34534876 DOI: 10.1016/j.yebeh.2021.108311] [Reference Citation Analysis]
3 Krief S, Berrebi-Bertrand I, Nagmar I, Giret M, Belliard S, Perrin D, Uguen M, Robert P, Lecomte JM, Schwartz JC, Finance O, Ligneau X. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol. Pharmacol Res Perspect 2021;9:e00855. [PMID: 34423920 DOI: 10.1002/prp2.855] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Videnovic A, Amara AW, Comella C, Schweitzer PK, Emsellem H, Liu K, Sterkel AL, Gottwald MD, Steinerman JR, Jochelson P, Zomorodi K, Hauser RA. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Mov Disord 2021. [PMID: 34191352 DOI: 10.1002/mds.28702] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Thorpy MJ. Recently Approved and Upcoming Treatments for Narcolepsy. CNS Drugs 2020;34:9-27. [PMID: 31953791 DOI: 10.1007/s40263-019-00689-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 21.0] [Reference Citation Analysis]
6 Cuomo MC, Sheehan AH, Jordan JK. Solriamfetol for the Management of Excessive Daytime Sleepiness. J Pharm Pract 2021;:8971900211009080. [PMID: 33882756 DOI: 10.1177/08971900211009080] [Reference Citation Analysis]
7 Zomorodi K, Chen D, Lee L, Swearingen D, Carter LP. A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. Clin Pharmacol Drug Dev 2021;10:404-13. [PMID: 32935460 DOI: 10.1002/cpdd.867] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Köteles I, Foroughbakhshfasaei M, Dobó M, Ádám M, Boldizsár I, Szabó Z, Tóth G. Determination of the Enantiomeric Purity of Solriamfetol by High-Performance Liquid Chromatography in Polar Organic Mode Using Polysaccharide-Type Chiral Stationary Phases. Chromatographia 2020;83:909-13. [DOI: 10.1007/s10337-020-03911-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Javaheri S, Javaheri S. Update on Persistent Excessive Daytime Sleepiness in OSA. Chest 2020;158:776-86. [PMID: 32147246 DOI: 10.1016/j.chest.2020.02.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 6.5] [Reference Citation Analysis]
10 Yang J, Gao J. Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy. Expert Review of Clinical Pharmacology 2019;12:723-8. [DOI: 10.1080/17512433.2019.1632705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Markham A. Solriamfetol: First Global Approval. Drugs 2019;79:785-90. [DOI: 10.1007/s40265-019-01123-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
12 Zomorodi K, Chen D, Lee L, Lasseter K, Marbury T. Single-Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End-Stage Renal Disease Requiring Hemodialysis. J Clin Pharmacol 2019;59:1120-9. [PMID: 30865315 DOI: 10.1002/jcph.1402] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]